Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
The best approach uses careful lab tests, close observation, and expert advice
I think it just goes to patients educating themselves on these medications and the potential side effects, and ranking the benefits of them versus potential risks
A clinical study of a GLP-1 RA highlighted that participants who followed dietary advice and injected weekly saw an average 18% lower energy intake compared to placebo, with significant reductions in body weight and cardio-metabolic risk
Other GLP-1 agonists include dulaglutide (Trulicity), liraglutide (Saxenda and Victoza), exenatide (Bydueron and Byetta), semaglutide (Rybelsus), and tirzepatide (Mounjaro)
All reviews and opinions are our own
A 2022 study found patients regained approximately two-thirds of lost weight within one year of stopping (Wilding et al., Diabetes Obesity and Metabolism 2022)
